LGALS1 Antibodies

Structure of LGALS1

The LGALS1 gene encodes a galectin-1 protein with a molecular weight of approximately 14.5 kDa, which is a homodimeric protein. The monomer of this protein consists of 135 amino acids. This protein is highly conserved in evolution, and the amino acid sequence similarity among different species can reach over 80%.

The three-dimensional structure of this protein exhibits a typical β-triangular folding pattern, consisting of two barrel-shaped domains formed by six antiparallel β-strands. Each monomer contains a conserved sugar recognition domain (CRD), which is composed of β-sheet and loop regions and forms a hydrophobic core. The highly conserved amino acid residues in the CRD (such as His44, Asn46, Arg48, Val59, and Asn61) are mediated by a hydrogen bond network for specific binding to β-galactosides. The two monomers form a functional dimer with two sugar binding sites through hydrophobic interactions, and this dimerization state is crucial for its cross-linking of sugar ligands and induction of cell signal transduction.

Fig. 1 The genetic architecture of LGALS1 gene.¹

Key structural properties of LGALS1:

• Typical β-triangular sandwich folding structure
• Hydrophobic cores formed by two antiparallel β-folds
• Each subunit contains a conserved sugar recognition domain (CRD)
• Highly conserved dimer interfaces mediate homologous dimerization

Functions of LGALS1

The LGALS1 gene encodes the galectin-1 protein, which primarily functions in recognizing β-galactosides and mediating interactions between cells and between cells and the extracellular matrix. This protein is involved in regulating cell adhesion, proliferation, and apoptosis, and also plays a role in maintaining immune homeostasis.

This protein regulates signal transduction in a dose-dependent manner by recognizing the polyglucosamine structure on the cell surface and in the extracellular matrix. Its biological effects are cell type-specific and concentration-dependent. At low concentrations, it promotes cell adhesion, while at high concentrations, it induces apoptosis.

Applications of LGALS1 and LGALS1 Antibody in Literature

1. Chen, Yu, et al. "Functional variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to influenza A (H7N9)." Scientific reports 5.1 (2015): 8517. https://doi.org/10.1038/srep08517

This study, through genome-wide association analysis, discovered that functional variations in the LGALS1 gene affect its expression level, thereby leading to differences in individual susceptibility to the H7N9 avian influenza virus. Among them, the haplotype GG of rs4820294/rs2899292 was significantly associated with a lower infection risk, and was also correlated with increased mRNA and protein expression levels of this gene.

2. Qin, Huanhuan, et al. "A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells." Cell Death & Disease 15.7 (2024): 482. https://doi.org/10.1038/s41419-024-06865-6

The study found that LGALS1 is highly expressed in leukemia stem cells and is associated with poor prognosis in patients with acute myeloid leukemia. Inhibiting LGALS1 can reduce lipid accumulation, inhibit cancer cell proliferation and promote apoptosis, providing a potential target for clinical prognosis assessment and individualized treatment.

3. Finotto, Lise, et al. "Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma." EMBO molecular medicine 15.11 (2023): EMMM202318144. https://doi.org/10.15252/emmm.202318144

The study, through single-cell sequencing and zebrafish models, revealed that glioblastoma stem cells regulate tumor-associated macrophages via LGALS1, inducing an immunosuppressive microenvironment. LGALS1 is a crucial immune regulatory factor, and its expression level is associated with the patient's survival period.

4. Triguero-Martínez, Ana, et al. "Genetic LGALS1 variants are associated with heterogeneity in galectin-1 serum levels in patients with early arthritis." International Journal of Molecular Sciences 23.13 (2022): 7181. https://doi.org/10.3390/ijms23137181

Genotyping studies on patients with early arthritis revealed that specific genetic variations of LGALS1 (such as rs9622682) were associated with elevated levels of galectin-1 and decreased levels of IL-6. Patients carrying the specific genotype showed higher expression of Gal1 after treatment, suggesting that this gene regulates the inflammatory response.

5. Sun, Huanhuan, et al. "NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression." Molecular cancer 21.1 (2022): 55. https://doi.org/10.1186/s12943-022-01533-9

The study found that NCAPG is a new oncogenic driver gene for non-small cell lung cancer, and its high expression is associated with poor prognosis of patients. Mechanistically, the function of NCAPG is closely related to LGALS1, which is also upregulated in lung cancer and may directly interact with it.

Creative Biolabs: LGALS1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality LGALS1 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom LGALS1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our LGALS1 antibodies, custom preparations, or technical support, contact us at email.